Current Report Filing (8-k)
January 14 2021 - 5:11PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
January 14, 2021
Date of Report (Date of earliest event reported)
DBV
Technologies S.A.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
France
|
|
001-36697
|
|
Not applicable
|
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
|
177-181 avenue Pierre Brossolette
92120 Montrouge France
|
|
|
|
Not Applicable
|
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrant’s telephone number, including area code: +33 1 55 42 78 78
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
|
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17
CFR 240.14a-12)
|
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
|
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
Ordinary shares, nominal value €0.10 per share
|
|
n/a
|
|
The Nasdaq Stock Market LLC*
|
|
American Depositary Shares, each representing one- half of one ordinary share, nominal value €0.10 per share
|
|
DBVT
|
|
The Nasdaq Stock Market LLC
|
|
*
|
Not for trading, but only in connection with the listing of the American Depositary Shares on The Nasdaq
Stock Market LLC.
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities
Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange
Act. ☐
On January 14, 2021, DBV Technologies S.A. (the “Company”) issued a press release announcing the Company’s receipt from the U.S. Food and
Drug Administration (“FDA”) of written responses to questions provided in the Type A meeting request the Company submitted in October 2020. The Type A meeting request was submitted following the Company’s receipt of a Complete
Response Letter from the FDA in connection with the Company’s Biologics License Application for Viaskin™ Peanut (DBV712), an investigational,
non-invasive, once-daily epicutaneous patch to treat peanut allergy in children ages 4 to 11 years. A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated by
reference herein.
|
Item 9.01
|
Financial Statements and Exhibits
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: January 14, 2021
|
|
|
|
DBV TECHNOLOGIES S.A.
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Sébastien Robitaille
|
|
|
|
|
|
Name: Sébastien Robitaille
Title: Chief Financial Officer
|
DBV Technologies Boulogn... (GM) (USOTC:DBVTF)
Historical Stock Chart
From Mar 2024 to Apr 2024
DBV Technologies Boulogn... (GM) (USOTC:DBVTF)
Historical Stock Chart
From Apr 2023 to Apr 2024
